Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25182222 | 0.91 | PIK3CA (0.40) | PIK3CACYP1B1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL30373773 | 0.88 | PIK3CA (0.40) | PIK3CACYP1B1AKT1AKT2AKT3 | |
| SCHEMBL25181484 | 0.88 | PIK3CA (0.40) | PIK3CACYP1B1AKT1AKT2AKT3 | |
| SCHEMBL25170996 | 0.88 | CYP1B1 (0.47) | PIK3CACYP1B1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL31035385 | 0.86 | PIK3CA (0.41) | PIK3CACYP1B1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL30373827 | 0.81 | CYP1B1 (0.36) | PIK3CACYP1B1 | |
| SCHEMBL25185328 | 0.81 | CYP1B1 (0.36) | PIK3CACYP1B1 | |
| SCHEMBL30373603 | 0.80 | CYP1B1 (0.38) | PIK3CACYP1B1 | |
| SCHEMBL25182220 | 0.80 | CYP1B1 (0.38) | PIK3CACYP1B1 | |
| SCHEMBL25177482 | 0.79 | PIK3CA (0.42) | PIK3CACYP1B1PIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230147285-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230147285-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230147285-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, PIK3R4, PIK3R5 | PIK3CA 1/4885CYP1B1 497/4885AKT1 15/4885 |
| US-20230147285-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | PIK3CA 1/4885CYP1B1 497/4885AKT1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.